Skip to main content
Erschienen in: Obesity Surgery 9/2016

21.01.2016 | Original Contributions

The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study

verfasst von: Lieke Mitrov-Winkelmolen, Marie-Christine W. van Buul-Gast, Dingeman J. Swank, Hans W P M Overdiek, Ron H. N. van Schaik, Daan J. Touw

Erschienen in: Obesity Surgery | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Data on the absorption of orally administered drugs following Roux-en-Y gastric bypass (RYGB) surgery in obese patients are limited and inconclusive. As it is difficult to predict changes in absorption, studies on frequently used drugs in this population are necessary. Acetylsalicylic acid (ASA) and omeprazole are two commonly prescribed drugs in obese patients.

Methods

In this repeated measures study, omeprazole and salicylic acid (SA) serum concentrations were measured before and after RYGB in 34 morbidly obese subjects. Time to maximum concentration (Tmax), lag time (Tlag), maximum concentration (Cmax), and area under the serum concentration versus time curve (AUC) were calculated for both drugs to determine possible differences in drug absorption after the procedure.

Results

For SA, Tmax significantly decreased after RYGB, while both Cmax and AUC0–24 significantly increased. For omeprazole, both Tmax and Tlag significantly decreased after RYGB, while Cmax significantly increased. Mean AUC0–12 significantly decreased post-surgery. The difference in AUC0–12 before and after surgery varied between subjects.

Conclusions

Our study shows a faster absorption of both ASA and omeprazole after RYGB. The exposure to ASA is higher post-surgery, but the standard dose of 80 mg does not need to be modified, considering its range in effective dose. The exposure to omeprazole is, on average, decreased after surgery. Clinicians should be aware to increase the dose of omeprazole if symptoms suggest inadequate response.
Literatur
3.
Zurück zum Zitat Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46(1):130–6.CrossRefPubMed Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46(1):130–6.CrossRefPubMed
4.
Zurück zum Zitat Padwal R. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. Padwal R. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50.
5.
Zurück zum Zitat Yska JP, van der Linde S, Tapper VV, Apers JA, Emous M, Totte ER, et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obes Surg. 2013;23(6):819–25.CrossRefPubMed Yska JP, van der Linde S, Tapper VV, Apers JA, Emous M, Totte ER, et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obes Surg. 2013;23(6):819–25.CrossRefPubMed
6.
Zurück zum Zitat Titus R, Kastenmeier A, Otterson MF. Consequences of gastrointestinal surgery on drug absorption. Nutr Clin Pract. 2013;28(4):429–36.CrossRefPubMed Titus R, Kastenmeier A, Otterson MF. Consequences of gastrointestinal surgery on drug absorption. Nutr Clin Pract. 2013;28(4):429–36.CrossRefPubMed
7.
Zurück zum Zitat Sawaya RA, Jaffe J, Friedenberg L, Friedenberg FK. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab. 2012;13(9):1345–55.CrossRefPubMedPubMedCentral Sawaya RA, Jaffe J, Friedenberg L, Friedenberg FK. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab. 2012;13(9):1345–55.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Fuller AK, Tingle D, DeVane CL, Scott JA, Stewart RB. Haloperidol pharmacokinetics following gastric bypass surgery. J Clin Psychopharmacol. 1986;6(6):376–8.PubMed Fuller AK, Tingle D, DeVane CL, Scott JA, Stewart RB. Haloperidol pharmacokinetics following gastric bypass surgery. J Clin Psychopharmacol. 1986;6(6):376–8.PubMed
9.
Zurück zum Zitat Hamad GG, Helsel JC, Perel JM, Kozak GM, McShea MC, Hughes C, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169(3):256–63.CrossRefPubMedPubMedCentral Hamad GG, Helsel JC, Perel JM, Kozak GM, McShea MC, Hughes C, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169(3):256–63.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med. 2007;20(3):310–3.CrossRefPubMed Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med. 2007;20(3):310–3.CrossRefPubMed
11.
Zurück zum Zitat Prince RA, Pincheira JC, Mason EE, Printen KJ. Influence of bariatric surgery on erythromycin absorption. J Clin Pharmacol. 1984;24(11–12):523–7.CrossRefPubMed Prince RA, Pincheira JC, Mason EE, Printen KJ. Influence of bariatric surgery on erythromycin absorption. J Clin Pharmacol. 1984;24(11–12):523–7.CrossRefPubMed
12.
Zurück zum Zitat Roerig JL, Steffen K, Zimmerman C, Mitchell JE, Crosby RD, Cao L. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8(1):62–6.CrossRefPubMed Roerig JL, Steffen K, Zimmerman C, Mitchell JE, Crosby RD, Cao L. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8(1):62–6.CrossRefPubMed
13.
Zurück zum Zitat Skottheim IB, Stormark K, Christensen H, Jakobsen GS, Hjelmesaeth J, Jenssen T, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009;86(3):311–8.CrossRefPubMed Skottheim IB, Stormark K, Christensen H, Jakobsen GS, Hjelmesaeth J, Jenssen T, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009;86(3):311–8.CrossRefPubMed
14.
Zurück zum Zitat Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy. 2010;30(2):217.CrossRefPubMed Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy. 2010;30(2):217.CrossRefPubMed
15.
Zurück zum Zitat Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008;22(3):281–91.CrossRefPubMedPubMedCentral Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008;22(3):281–91.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Rubio IG, Galrao AL, Santo MA, Zanini AC, Medeiros-Neto G. Levothyroxine absorption in morbidly obese patients before and after Roux-En-Y gastric bypass (RYGB) surgery. Obes Surg. 2012;22(2):253–8.CrossRefPubMed Rubio IG, Galrao AL, Santo MA, Zanini AC, Medeiros-Neto G. Levothyroxine absorption in morbidly obese patients before and after Roux-En-Y gastric bypass (RYGB) surgery. Obes Surg. 2012;22(2):253–8.CrossRefPubMed
17.
Zurück zum Zitat Hamilton R, Thai XC, Ameri D, Pai MP. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother. 2013;68(3):666–73.CrossRefPubMed Hamilton R, Thai XC, Ameri D, Pai MP. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother. 2013;68(3):666–73.CrossRefPubMed
18.
Zurück zum Zitat De Smet J, Colin P, De PP, Ruige J, Batens H, Van NY, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother. 2012;67(1):226–9.CrossRefPubMed De Smet J, Colin P, De PP, Ruige J, Batens H, Van NY, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother. 2012;67(1):226–9.CrossRefPubMed
21.
Zurück zum Zitat Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.CrossRef Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.CrossRef
22.
Zurück zum Zitat Hunfeld NGM. Clinical effects of proton pump inhibitors, Focus on pharmacogenetics, kinetics and dynamics. Rotterdam: Erasmus University Rotterdam; 2010. Hunfeld NGM. Clinical effects of proton pump inhibitors, Focus on pharmacogenetics, kinetics and dynamics. Rotterdam: Erasmus University Rotterdam; 2010.
23.
Zurück zum Zitat D’Hondt MA, Pottel H, Devriendt D, Van RF, Vansteenkiste F. Can a short course of prophylactic low-dose proton pump inhibitor therapy prevent stomal ulceration after laparoscopic Roux-en-Y gastric bypass? Obes Surg. 2010;20(5):595–9.CrossRefPubMed D’Hondt MA, Pottel H, Devriendt D, Van RF, Vansteenkiste F. Can a short course of prophylactic low-dose proton pump inhibitor therapy prevent stomal ulceration after laparoscopic Roux-en-Y gastric bypass? Obes Surg. 2010;20(5):595–9.CrossRefPubMed
24.
Zurück zum Zitat Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery. Surg Obes Relat Dis. 2006;2(4):455–9.CrossRefPubMed Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery. Surg Obes Relat Dis. 2006;2(4):455–9.CrossRefPubMed
25.
Zurück zum Zitat Garrido Jr AB, Rossi M, Lima Jr SE, Brenner AS, Gomes Jr CA. Early marginal ulcer following Roux-en-Y gastric bypass under proton pump inhibitor treatment: prospective multicentric study. Arq Gastroenterol. 2010;47(2):130–4.CrossRef Garrido Jr AB, Rossi M, Lima Jr SE, Brenner AS, Gomes Jr CA. Early marginal ulcer following Roux-en-Y gastric bypass under proton pump inhibitor treatment: prospective multicentric study. Arq Gastroenterol. 2010;47(2):130–4.CrossRef
27.
Zurück zum Zitat van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, et al. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011;12(8):1137–46.CrossRefPubMed van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, et al. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011;12(8):1137–46.CrossRefPubMed
29.
Zurück zum Zitat Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262–9.CrossRefPubMed Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258(2):262–9.CrossRefPubMed
Metadaten
Titel
The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study
verfasst von
Lieke Mitrov-Winkelmolen
Marie-Christine W. van Buul-Gast
Dingeman J. Swank
Hans W P M Overdiek
Ron H. N. van Schaik
Daan J. Touw
Publikationsdatum
21.01.2016
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 9/2016
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2065-8

Weitere Artikel der Ausgabe 9/2016

Obesity Surgery 9/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.